Do analysts recommend BPTH or VTGN?

VistaGen Therapeutics has a consensus target price of $0.95, indicating a potential upside of 281.68%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe VistaGen Therapeutics is more favorable than Bio-Path. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 VistaGen Therapeutics 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Is BPTH or VTGN more profitable?

Bio-Path has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. VistaGen Therapeutics' return on equity of -133.02% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% VistaGen Therapeutics -5,487.01% -133.02% -105.79%

Is EGRX or BPTH more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A Bio-Path N/A -2,842.40% -337.48%

Do analysts rate BPTH or RVPH?

Reviva Pharmaceuticals has a consensus target price of $66.67, indicating a potential upside of 10,001.01%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Bio-Path. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Reviva Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable valuation and earnings, BPTH or RVPH?

Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A Reviva Pharmaceuticals N/A N/A -$19.86M -$4.06 N/A

Is BPTH or RVPH more profitable?

Reviva Pharmaceuticals' return on equity of -391.58% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% Reviva Pharmaceuticals N/A -391.58% -119.08%

Do analysts prefer TRAW or BPTH?

Traws Pharma currently has a consensus price target of $1.00, suggesting a potential upside of 30.26%. Given Traws Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Traws Pharma is more favorable than Bio-Path. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is TRAW or BPTH more profitable?

Traws Pharma's return on equity of -913.18% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -913.18% -133.88% Bio-Path N/A -2,842.40% -337.48%

Do analysts rate PMCB or BPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, PMCB or BPTH?

Nuvilex is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvilex N/A N/A $30.66M -$1.12 N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is PMCB or BPTH more profitable?

Nuvilex's return on equity of 2.13% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 2.13% 1.69% Bio-Path N/A -2,842.40% -337.48%

Bio-Path (BPTH) Competitors

$0.05 0.00 (0.00%)

As of 07/2/2026 03:01 PM Eastern

Compare

BPTH vs. VTGN, EGRX, RVPH, TRAW, and PMCB

Should you buy Bio-Path stock or one of its competitors? MarketBeat compares Bio-Path with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bio-Path include VistaGen Therapeutics (VTGN), Eagle Pharmaceuticals (EGRX), Reviva Pharmaceuticals (RVPH), Traws Pharma (TRAW), and Nuvilex (PMCB). These companies are all part of the "pharmaceutical products" industry.

How does Bio-Path compare to VistaGen Therapeutics?

Bio-Path (NASDAQ:BPTH) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

In the previous week, VistaGen Therapeutics had 5 more articles in the media than Bio-Path. MarketBeat recorded 5 mentions for VistaGen Therapeutics and 0 mentions for Bio-Path. Bio-Path's average media sentiment score of 0.00 beat VistaGen Therapeutics' score of -0.56 indicating that Bio-Path is being referred to more favorably in the media.

Company	Overall Sentiment
Bio-Path	Neutral
VistaGen Therapeutics	Negative

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

VistaGen Therapeutics has a consensus target price of $0.95, indicating a potential upside of 281.68%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe VistaGen Therapeutics is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Bio-Path has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. VistaGen Therapeutics' return on equity of -133.02% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%

Bio-Path has a beta of -0.52, meaning that its share price is 152% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

Bio-Path has higher earnings, but lower revenue than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
VistaGen Therapeutics	$1.27M	8.05	-$69.68M	-$1.83	N/A

Summary

VistaGen Therapeutics beats Bio-Path on 9 of the 14 factors compared between the two stocks.

How does Bio-Path compare to Eagle Pharmaceuticals?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Eagle Pharmaceuticals' return on equity of 0.00% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Bio-Path	N/A	-2,842.40%	-337.48%

Eagle Pharmaceuticals has higher revenue and earnings than Bio-Path. Bio-Path is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.57
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

In the previous week, Eagle Pharmaceuticals' average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
Bio-Path	Neutral

Eagle Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.52, suggesting that its stock price is 152% less volatile than the broader market.

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Eagle Pharmaceuticals beats Bio-Path on 9 of the 9 factors compared between the two stocks.

How does Bio-Path compare to Reviva Pharmaceuticals?

Bio-Path (NASDAQ:BPTH) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Reviva Pharmaceuticals has a consensus target price of $66.67, indicating a potential upside of 10,001.01%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

Reviva Pharmaceuticals' return on equity of -391.58% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Bio-Path has a beta of -0.52, suggesting that its share price is 152% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Reviva Pharmaceuticals had 1 more articles in the media than Bio-Path. MarketBeat recorded 1 mentions for Reviva Pharmaceuticals and 0 mentions for Bio-Path. Bio-Path's average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Bio-Path	Neutral
Reviva Pharmaceuticals	Neutral

Summary

Reviva Pharmaceuticals beats Bio-Path on 9 of the 12 factors compared between the two stocks.

How does Bio-Path compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Traws Pharma's average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company	Overall Sentiment
Traws Pharma	Neutral
Bio-Path	Neutral

Traws Pharma currently has a consensus price target of $1.00, suggesting a potential upside of 30.26%. Given Traws Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Traws Pharma is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Traws Pharma's return on equity of -913.18% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
Bio-Path	N/A	-2,842.40%	-337.48%

Traws Pharma has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.52, indicating that its stock price is 152% less volatile than the broader market.

Traws Pharma has higher revenue and earnings than Bio-Path. Traws Pharma is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.73M	2.85	$9.17M	-$1.69	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

7.9% of Traws Pharma shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 7.6% of Traws Pharma shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Traws Pharma beats Bio-Path on 9 of the 11 factors compared between the two stocks.

How does Bio-Path compare to Nuvilex?

Nuvilex (NASDAQ:PMCB) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Nuvilex has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.52, indicating that its stock price is 152% less volatile than the broader market.

Nuvilex's return on equity of 2.13% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
Bio-Path	N/A	-2,842.40%	-337.48%

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Nuvilex's average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company	Overall Sentiment
Nuvilex	Neutral
Bio-Path	Neutral

Nuvilex is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Summary

Nuvilex beats Bio-Path on 7 of the 9 factors compared between the two stocks.

Get Bio-Path News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPTH vs. The Competition

Export

Metric	Bio-Path	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.36M	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	-0.04	1.66	28.02	24.70
Price / Sales	N/A	127.11	540.37	99.49
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	0.07	8.17	10.96	6.46
Net Income	-$16.08M	-$3.71M	$3.57B	$337.01M
7 Day Performance	N/A	2.59%	2.12%	1.69%
1 Month Performance	N/A	4.41%	5.25%	3.81%
1 Year Performance	N/A	49.43%	33.29%	23.90%

Bio-Path Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPTH Bio-Path	N/A	$0.05 flat	N/A	-72.5%	$2.36M	N/A	N/A	10	Gap Down
VTGN VistaGen Therapeutics	2.7657 of 5 stars	$0.22 -1.8%	$0.95 +327.9%	-87.7%	$8.95M	$1.27M	N/A	40	News Coverage Gap Down
EGRX Eagle Pharmaceuticals	N/A	$0.67 flat	N/A	N/A	$8.70M	$257.55M	0.57	100
RVPH Reviva Pharmaceuticals	2.4127 of 5 stars	$0.66 +4.9%	$66.67 +10,004.1%	-91.0%	$8.65M	N/A	N/A	5	News Coverage Analyst Upgrade Gap Up
TRAW Traws Pharma	3.4192 of 5 stars	$0.84 -1.0%	$1.00 +19.8%	-46.3%	$8.36M	$2.79M	N/A	17	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BPTH) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Path (BPTH) Competitors

BPTH vs. VTGN, EGRX, RVPH, TRAW, and PMCB

How does Bio-Path compare to VistaGen Therapeutics?

Summary

How does Bio-Path compare to Eagle Pharmaceuticals?

Summary

How does Bio-Path compare to Reviva Pharmaceuticals?

Summary

How does Bio-Path compare to Traws Pharma?

Summary

How does Bio-Path compare to Nuvilex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH vs. The Competition

Bio-Path Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Path (BPTH) Competitors

BPTH vs. VTGN, EGRX, RVPH, TRAW, and PMCB

How does Bio-Path compare to VistaGen Therapeutics?

Does the media refer more to BPTH or VTGN?

Do institutionals and insiders believe in BPTH or VTGN?

Do analysts recommend BPTH or VTGN?

Is BPTH or VTGN more profitable?

Which has more volatility & risk, BPTH or VTGN?

Which has higher earnings & valuation, BPTH or VTGN?

Summary

How does Bio-Path compare to Eagle Pharmaceuticals?

Is EGRX or BPTH more profitable?

Which has higher valuation & earnings, EGRX or BPTH?

Does the media prefer EGRX or BPTH?

Which has more risk and volatility, EGRX or BPTH?

Do institutionals and insiders believe in EGRX or BPTH?

Summary

How does Bio-Path compare to Reviva Pharmaceuticals?

Do analysts rate BPTH or RVPH?

Which has preferable valuation and earnings, BPTH or RVPH?

Is BPTH or RVPH more profitable?

Which has more risk & volatility, BPTH or RVPH?

Do insiders and institutionals believe in BPTH or RVPH?

Does the media favor BPTH or RVPH?

Summary

How does Bio-Path compare to Traws Pharma?

Does the media refer more to TRAW or BPTH?

Do analysts prefer TRAW or BPTH?

Is TRAW or BPTH more profitable?

Which has more risk and volatility, TRAW or BPTH?

Which has preferable earnings and valuation, TRAW or BPTH?

Do insiders and institutionals hold more shares of TRAW or BPTH?

Summary

How does Bio-Path compare to Nuvilex?

Do analysts rate PMCB or BPTH?

Which has more risk and volatility, PMCB or BPTH?

Is PMCB or BPTH more profitable?

Do insiders & institutionals have more ownership in PMCB or BPTH?

Does the media favor PMCB or BPTH?

Which has preferable earnings & valuation, PMCB or BPTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH vs. The Competition

Bio-Path Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools